FDA Approvals of Jemperli (dostarlimab-gxly)

Jemperli ( Dostarlimab)

Cases of cancer in India as compared to the world

As per Cancer Statistics Report, India‘s cancer growth rate is the highest globally. Cancer cases increased at an average annual rate of 1.1-2 percent from 2010-2019. 

According to Cancer Statistics, 2020. Report from National Cancer Registry Programme, India – The projected number of patients with cancer in India is 1,392,179 for the year 2020. The common five leading sites of cancers are breast, lung, mouth, cervix uteri, and tongue. The cancer percentage rate showed an increase in all sites of cancer in both sexes. The majority of patients with cancer were diagnosed at the locally advanced stage with breast ( 57.0%), cervix uteri (60.0%), head and neck (66.6%), and stomach (50.8%) cancer. Advance cancer was principal among males (44.0%) and females (47.6%).

According to global cancer data., Globally, the cases of cancer diagnosed in 2020 were 18,094,716 million. The age-standardized rate for all cancers for men and women combined was 190 per 100,000 in 2020. The rate was higher for men (206.9 per 100,000) and women (1678.1 per 100,000).

The age-standardized rate was at least 300 per 100,000 for 10 countries : 

Denmark, Ireland, Hungary, Belgium, France, The Netherlands, Australia, Norway, France ( New Caledonia), and Slovenia. 

In men, the highest cancer rate was found in Hungary at 371 men per 100,000 while in women, the highest cancer rate was found in Denmark at 328.3 women per 100,000.

Jemperli (Dostarlimab)

Active ingredient – dostarlimab – gxly

Inactive Ingredients – Citric acid monohygrate, L-arginine hydrochloride, polysorbate 80, sodium chloride, trisodium citrate dihydrate, and water for injection.

Jamperli is the brand name of Dostarlimab. It is an anti-programmed cell death receptor used for the treatment of adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumor and advanced endometrial cancer.

Dostarlimab was discovered by American biotechnology firm AnaptysBio using its exclusive somatic hypermutation antibody platform. This drug was licensed to the US based on an exclusive license and collaboration agreement in March 2014. This drug is available in 500mg/10mi or 50ml dosage strength as a clear to slightly Multicolore, colorless to yellow solution in a single dose for connected to a vein infusion.

It joined GlaxoSmithKline’s (GSK) portfolio in 2019 after GSK acquired Tesaro. 

GSK is responsible for the research, development, commercialization, and manufacturing of the antibody. In May 2019, Dostarlimab was granted therapy designation by the US Food and Drug Administration (FDA) for recurrent or advanced dMMR endometrial cancer.

In April 2021, the FDA approved Jemperli solid tumor patient. In the same month, the therapy was approved by European Commission becoming the first anti-PD-1 therapy available for endometrial cancer in Europe.

A drug trial has been done to know its effects. This drug trial has been done on twelve patients. It was a small clinical trial where patients with rectal cancers were put on immunotherapy for 6 months. This drug trial miraculously removed tumors from a few patients who took a drug called Dostarlimab. This drug is also useful in a section of rectal cancer patients who have a specific genetic abnormality which is known as MMR, which is known as mismatch repair gene deficiency.

Mismatch Repair deficiency (MMD) :

Mismatch repair deficiency is a rare disorder that increases the risk of developing one or more types of cancer in children and adults. It is a cell that has many DNA mutations, which may lead to cancer. The most common occurrence of MMD syndrome are cancers of the colorectal, gastrointestinal, endometrial, breast, prostate, bladder, and thyroid.

Colorectal cancer

Cancer that begins in the colon is called colon cancer, while cancer in the rectum is known as rectal cancer. Cancers that affect either of these organs may be called colorectal cancer.

It usually begins as small noncancerous clumps of cells called polyps that form inside the colon. Later on, these polyps can become colon cancers. It is sometimes called colorectal cancer, which combines colon and rectal cancer that begins in the rectum.

Symptoms of colorectal cancer include:

  • Change in bowel movements
  • Blood on or in the stool
  • Anemia
  • Abdominal and pelvic pain
  • Bloating
  • Weight loss
  • Vomiting

Gastrointestinal cancer

Gastrointestinal cancer is common cancer in adults that start in special cells in the walls of the gastrointestinal tract. It is also known as the digestive tract. Gastrointestinal cancer is the growth of cells that form a special type of nerve cell. These special nerve cells are in the walls of the digestive organs. Small cancer may cause no symptoms. As it grows, it can cause some signs and symptoms.

Some signs and symptoms include :

  • Abdominal pain
  • Fatigue
  • Nausea
  • Vomiting
  • Cramps in the abdomen after eating
  • Loss of appetite
  • Dark colon stool
  • Bleeding in the digestive system.

Endometrial cancer

Endometrial cancer is a type of cancer that begins in the uterus. This cancer starts when cells in the endometrium ( the inner lining of the uterus) start to grow out of control. Cells in any part of the body can become cancer. It can spread to other parts of the body. This cancer is sometimes called uterine cancer.

Signs and symptoms of endometrial cancer include :

  • Vaginal bleeding
  • Bleeding between periods
  • Pelvic pain

Breast cancer

Breast cancer originates in breast tissue. It occurs when breast cells change and grow out of control. It creates a mass of tissue called a tumor. Breast cancer can occupy and grow into the tissue surrounding the breast. It spread to other parts of the body and forms new tumors. This stage is called metastasis (advanced cancer).

Signs and symptoms of breast cancer include :

  • A change in the size, shape, or texture of the breast.
  • A mass or lumps in the breast
  • Change in the skin and nipple of the breast.
  • Redness of the skin
  • Clear fluid discharge

Prostate cancer

Prostate cancer is a common type of cancer in males. It begins when cells in the prostate gland start to grow out of control. It can then spread to other parts of the body. It makes some of the fluid that is part of semen. Many prostate cancer grows slowly but they may not cause serious harm. While some prostate cancer needs treatment and can spread quickly.

Signs and symptoms of prostate cancer include :

  • Difficulty in urination
  • A frequent urge to urinate
  • A weak urine stream
  • Blood in the urine
  • Painful urination
  • Pain in the back, hips, or pelvis

Bladder cancer

Bladder cancer is a disease in which cancer cells form in the tissues of the bladder. Smoking can affect the risk of bladder cancer.

Signs and symptoms of bladder cancer include :

  • Blood in the urine
  • Frequent urination
  • Pain during urination
  • Lower back pain.

Thyroid cancer

Thyroid cancer is the growth of cells that starts in the thyroid. It does not cause any symptoms at first. This cancer develops when cells change and move. The abnormal cells begin multiplying in the thyroid to form a tumor. But later on, it grows, and it can cause some symptoms.

Some signs and symptoms of thyroid cancer include :

Neck pain

Throat pain

Lump in your neck

Difficult to swallow

Vocal changes


Use of Jamperli in the treatment of Mismatch repair deficiency

Jamperli is a kind of antibody, which works to improve the body’s immunity. It helps the body’s immune system to work and kill the cancer cells. All 12 patients have good responses at six months. It is a very effective treatment. Dostarlimab is now in the Indian market and will be available in a cancer center. 

How does Jamperli work?

Jamperli ( chemical name – dostarlimab- gxly) is a type of immunotherapy called an immune checkpoint inhibitor. Immune checkpoints are proteins in your body that help your immune system which indicates the difference between your cells and foreign cells such as harmful bacteria. 

Immune checkpoint inhibitors target these immune checkpoint proteins and help the immune system recognize and attack cancer cells. PD-1 is a type of checkpoint protein found in T-cells, which are immune system cells that move throughout the body looking for signs of disease or infection. PD-L1 is another checkpoint protein found on many healthy cells in the body. It works to stop T cells from killing a cancer cell. An immune checkpoint inhibitor medicine like Jamperli that stops the PD-1 from taping to PD-1 allows T cells to attack cancer cells and kill them.

Side effects of Jamperli

The most common side effects of jamperli include 

  • Tiredness
  • Weakness
  • Nausea
  • Diarrhea
  • Low red blood count (anemia) and

  • Constipation

These are some side effects. For more information, ask your healthcare provider.

Call your doctor to report the side effect and get good medical advice to get relief from the side effects.

How to take Jamperli?

This medicine should be taken in form of an injection given to you into the vein through an intravenous (IV) line over 30 minutes by your healthcare provider.

It is usually given every 3 weeks for the first 4 doses and then beginning 3 weeks later it is given every 6 weeks.

Dose and duration will decide your healthcare provider. 

A blood test to check for any kind of side effects. 

Ingredient use in Jemperli

Active ingredient – dostarlimab – gxly

Inactive Ingredients – Citric acid monohygrate, L-arginine hydrochloride, polysorbate 80, sodium chloride, trisodium citrate dihydrate, and water for injection.

It is not recommended for pregnant women, breastfeeding mothers, and children below 18 years of age.


Jamperli is a medicine that is used to treat mismatch repair deficiency which cannot be removed by surgery. It is used in the treatment of cancers such as thyroid, endometrial, breast, gastrointestinal, prostate, bladder, and colorectal cancer. It is given in form of an injection. It is a very effective medicine to stop or kill cancer cells. You may experience some side effects of this medicine. You can consult with your healthcare provider to prevent the side effects.

Leave a Reply